Targeting this pathway, for example, by enhancing SIRT5 activity to eliminate malonyl-CoA decarboxylase or by supplying malonyl-CoA decarboxylase to consume malonyl-CoA, could be a therapeutic strategy to protect the heart (and possibly other organs) in sepsis. The gene discussed is MLYCD; the disease is Sepsis.